Arete Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $279K | Buy |
+5,728
| New | +$279K | 0.02% | 585 |
|
|
2024
Q4 | – | Sell |
-10,376
| Closed | -$486K | – | 757 |
|
|
2024
Q3 | $486K | Sell |
10,376
-388
| -4% | -$18.2K | 0.04% | 383 |
|
|
2024
Q2 | $578K | Sell |
10,764
-133
| -1% | -$7.14K | 0.05% | 353 |
|
|
2024
Q1 | $743K | Sell |
10,897
-115
| -1% | -$7.84K | 0.07% | 251 |
|
|
2023
Q4 | $689K | Sell |
11,012
-589
| -5% | -$36.9K | 0.05% | 325 |
|
|
2023
Q3 | $527K | Buy |
11,601
+870
| +8% | +$39.5K | 0.09% | 227 |
|
|
2023
Q2 | $602K | Sell |
10,731
-283
| -3% | -$15.9K | 0.05% | 325 |
|
|
2023
Q1 | $498K | Buy |
11,014
+5,353
| +95% | +$242K | 0.04% | 343 |
|
|
2022
Q4 | $230M | Sell |
5,661
-2,160
| -28% | -$87.8M | 0.02% | 526 |
|
|
2022
Q3 | $511K | Buy |
7,821
+1,153
| +17% | +$75.3K | 0.05% | 294 |
|
|
2022
Q2 | $405K | Buy |
+6,668
| New | +$405K | 0.04% | 282 |
|
|
2021
Q4 | – | Sell |
-2,506
| Closed | -$277K | – | 506 |
|
|
2021
Q3 | $277K | Buy |
2,506
+54
| +2% | +$5.97K | 0.03% | 340 |
|
|
2021
Q2 | $303K | Buy |
+2,452
| New | +$303K | 0.04% | 263 |
|
|
2021
Q1 | – | Sell |
-1,598
| Closed | -$250K | – | 424 |
|
|
2020
Q4 | $250K | Buy |
+1,598
| New | +$250K | 0.04% | 341 |
|